Kendra A Young1, Amita Maturu2, Carlos Lorenzo3, Carl D Langefeld4, Lynne E Wagenknecht4, Yii-Der I Chen5, Kent D Taylor5, Jerome I Rotter5, Jill M Norris1, Neda Rasouli6. 1. Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States of America. 2. OhioHealth, Columbus, OH 43235, United States of America. 3. Department of Medicine, University of Texas Health Sciences Center, San Antonio, TX 78229, United States of America. 4. Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston Salem, NC 27157, United States of America. 5. Institute for Translational Genomics and Population Sciences and Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles, CA 90502, United States of America. 6. Division of Endocrinology, Diabetes and Metabolism, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States of America; VA Eastern Colorado Health Care System, Denver, CO 80220, United States of America. Electronic address: neda.rasouli@ucdenver.edu.
Abstract
OBJECTIVE: The TG/HDL-C ratio is used as a marker of insulin resistance (IR) in Caucasians; however, there is limited data in other ethnic groups. We hypothesized that the TG/HDL-C ratio is associated with IR in Hispanics and African Americans (AA). RESEARCH DESIGN AND METHODS: Data from the Insulin Resistance Atherosclerosis Family Study was examined for associations between TG/HDL-C ratio and IR, β-cell function and incident diabetes in non-diabetic Hispanics (n = 872, 63% female) and AA (n = 371, 61% female). Insulin sensitivity index (SI) and disposition index (DI) from frequently-sampled intravenous glucose tolerance tests were used as markers of IR and β-cell function respectively. Incident type 2 diabetes was determined by fasting glucose ≥ 126 mg/dl or initiation of anti-hyperglycemia agents over 5 year follow-up. RESULTS: Higher TG/HDL-C ratio was associated with IR in Hispanic and AA men and women (P < 0.0002), as well as β-cell function in Hispanic women and AA men and women (P < 0.02). TG/HDL-C predicted incident type 2 diabetes in women (area under the curves 0.703 and 0.795 for Hispanics and AA respectively). CONCLUSIONS: Similar to Caucasians, the TG/HDL-C ratio can be used to identify IR in Hispanics and AA, and may predict type 2 diabetes in women.
OBJECTIVE: The TG/HDL-C ratio is used as a marker of insulin resistance (IR) in Caucasians; however, there is limited data in other ethnic groups. We hypothesized that the TG/HDL-C ratio is associated with IR in Hispanics and African Americans (AA). RESEARCH DESIGN AND METHODS: Data from the Insulin Resistance Atherosclerosis Family Study was examined for associations between TG/HDL-C ratio and IR, β-cell function and incident diabetes in non-diabetic Hispanics (n = 872, 63% female) and AA (n = 371, 61% female). Insulin sensitivity index (SI) and disposition index (DI) from frequently-sampled intravenous glucose tolerance tests were used as markers of IR and β-cell function respectively. Incident type 2 diabetes was determined by fasting glucose ≥ 126 mg/dl or initiation of anti-hyperglycemia agents over 5 year follow-up. RESULTS: Higher TG/HDL-C ratio was associated with IR in Hispanic and AA men and women (P < 0.0002), as well as β-cell function in Hispanic women and AA men and women (P < 0.02). TG/HDL-C predicted incident type 2 diabetes in women (area under the curves 0.703 and 0.795 for Hispanics and AA respectively). CONCLUSIONS: Similar to Caucasians, the TG/HDL-C ratio can be used to identify IR in Hispanics and AA, and may predict type 2 diabetes in women.
Authors: Tracey McLaughlin; Gerald Reaven; Fahim Abbasi; Cindy Lamendola; Mohammed Saad; David Waters; Joel Simon; Ronald M Krauss Journal: Am J Cardiol Date: 2005-08-01 Impact factor: 2.778
Authors: Leora Henkin; Richard N Bergman; Donald W Bowden; Darrell L Ellsworth; Steven M Haffner; Carl D Langefeld; Braxton D Mitchell; Jill M Norris; Marian Rewers; Mohammed F Saad; Elizabeth Stamm; Lynne E Wagenknecht; Stephen S Rich Journal: Ann Epidemiol Date: 2003-04 Impact factor: 3.797
Authors: Lynne E Wagenknecht; Carl D Langefeld; Ann L Scherzinger; Jill M Norris; Steven M Haffner; Mohammed F Saad; Richard N Bergman Journal: Diabetes Date: 2003-10 Impact factor: 9.461
Authors: L E Wagenknecht; E J Mayer; M Rewers; S Haffner; J Selby; G M Borok; L Henkin; G Howard; P J Savage; M F Saad Journal: Ann Epidemiol Date: 1995-11 Impact factor: 3.797
Authors: Carlos Lorenzo; Lynne E Wagenknecht; Marian J Rewers; Andrew J Karter; Richard N Bergman; Anthony J G Hanley; Steven M Haffner Journal: Diabetes Care Date: 2010-09 Impact factor: 17.152
Authors: Cynthia A Moylan; Alisha M Mavis; Dereje Jima; Rachel Maguire; Mustafa Bashir; Jeongeun Hyun; Melanie N Cabezas; Alice Parish; Donna Niedzwiecki; Anna Mae Diehl; Susan K Murphy; Manal F Abdelmalek; Cathrine Hoyo Journal: Epigenetics Date: 2022-02-21 Impact factor: 4.861
Authors: Neda Rasouli; Naji Younes; Kristina M Utzschneider; Silvio E Inzucchi; Ashok Balasubramanyam; Andrea L Cherrington; Faramarz Ismail-Beigi; Robert M Cohen; Darin E Olson; Ralph A DeFronzo; William H Herman; John M Lachin; Steven E Kahn Journal: Diabetes Care Date: 2020-12-17 Impact factor: 17.152
Authors: Fatma Ben Cherifa; Jalila El Ati; Radhouene Doggui; Myriam El Ati-Hellal; Pierre Traissac Journal: Int J Environ Res Public Health Date: 2021-05-20 Impact factor: 3.390